title: Megazol combined with suramin improves a new diagnosis index of the early meningo-encephalitic phase of experimental African trypanosomiasis.
abstract: In human African trypanosomiasis (HAT), the parasites invade the central nervous system (CNS), leading to the development of meningo-encephalitis and an irreversible demyelinating process, which kills the patient unless specific treatment is undertaken. Among the experimental trypanocides, the nitroimidazole derivative megazol alone at optimal doses does not cure late-stage disease tested in mouse models, however the combination of suramin and megazol is able to cure infected mice without CNS involvement. We recently developed an experimental model of HAT with a sharp decrease in both the food intake and the body weight which may constitute an effective index of the early meningo-encephalitic phase. Using this model, we tested this hypothesis by the exclusive effectiveness of a megazol and suramin combination treatment to eliminate CNS trypanosomes. Sprague-Dawley rats were infected with Trypanosoma brucei brucei AnTat 1.1E. Food intake and body weight were measured daily from the day of infection to death. Haematocrit was measured twice a week. Treatment consisted of 20 mg suramin per kg body weight administered intraperitoneally (i.p.) alone, or three daily doses (80 mg/kg) of megazol given per os, or suramin (20 mg/kg, i.p.) followed 24 h later by three daily doses (80 mg/kg) of megazol given per os. Treatment was followed by an increase in daily body weight and food intake similar to those of the control animals, 2 weeks after treatment. The anaemia developed after infection is also cleared as shown by the haematocrit measurements. The rats treated with megazol alone died about 29 days after treatment and those treated with suramin, after about 26 days. Seven months later, no signs of relapse were seen in 10 of 12 rats treated with the therapeutic combination, indicating that this chemotherapy regimen was curative. The results support our previous finding, i.e. the decrease in body weight may constitute a diagnosis index of the early meningo-encephalitic phase.
authors.affiliation: Centre de recherches du Service de santé des armées, La Tronche, France. a_darsaud@yahoo.com
authors.forename: Annabelle
authors.initials: A
authors.lastname: Darsaud
authors.forename: Céline
authors.initials: C
authors.lastname: Chevrier
authors.forename: Lionel
authors.initials: L
authors.lastname: Bourdon
authors.forename: Michel
authors.initials: M
authors.lastname: Dumas
authors.forename: Alain
authors.initials: A
authors.lastname: Buguet
authors.forename: Bernard
authors.initials: B
authors.lastname: Bouteille
mesh_terms: D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D000818:Animals; D001835:Body Weight; D004359:Drug Therapy, Combination; D004435:Eating; D006400:Hematocrit / Q000379:methods; D008297:Male; D008590:Meningoencephalitis / Q000188:drug therapy* / Q000469:parasitology; D018512:Parasitemia / Q000188:drug therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D013498:Suramin / Q000627:therapeutic use*; D013830:Thiadiazoles / Q000627:therapeutic use*; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014346:Trypanosoma brucei brucei / Q000302:isolation & purification; D014353:Trypanosomiasis, African / Q000188:drug therapy* / Q000469:parasitology
chemical_list: D013830:Thiadiazoles; D014344:Trypanocidal Agents; C013378:megazol; D013498:Suramin